PL1765370T3 - Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS - Google Patents

Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS

Info

Publication number
PL1765370T3
PL1765370T3 PL05764629T PL05764629T PL1765370T3 PL 1765370 T3 PL1765370 T3 PL 1765370T3 PL 05764629 T PL05764629 T PL 05764629T PL 05764629 T PL05764629 T PL 05764629T PL 1765370 T3 PL1765370 T3 PL 1765370T3
Authority
PL
Poland
Prior art keywords
parapoxviruses
combination
aids
treatment
antiviral agents
Prior art date
Application number
PL05764629T
Other languages
English (en)
Inventor
Daniela Paulsen
Helga Rübsamen-Waigmann
Amar Kureishi
Gerhard Hunsmann
Christiane Stahl-Hennig
Andreas Meyerhans
Alexandra Schütz
Olaf Weber
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35115792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1765370(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of PL1765370T3 publication Critical patent/PL1765370T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05764629T 2004-07-13 2005-07-08 Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS PL1765370T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04016414 2004-07-13
EP05764629A EP1765370B1 (en) 2004-07-13 2005-07-08 Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
PCT/EP2005/007395 WO2006005529A1 (en) 2004-07-13 2005-07-08 Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids

Publications (1)

Publication Number Publication Date
PL1765370T3 true PL1765370T3 (pl) 2010-02-26

Family

ID=35115792

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05764629T PL1765370T3 (pl) 2004-07-13 2005-07-08 Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS

Country Status (13)

Country Link
US (1) US8343478B2 (pl)
EP (1) EP1765370B1 (pl)
JP (1) JP4897677B2 (pl)
CN (2) CN1984666A (pl)
AT (1) ATE442155T1 (pl)
BR (1) BRPI0513321B1 (pl)
CA (1) CA2573204C (pl)
DE (1) DE602005016552D1 (pl)
DK (1) DK1765370T3 (pl)
ES (1) ES2330540T3 (pl)
PL (1) PL1765370T3 (pl)
PT (1) PT1765370E (pl)
WO (1) WO2006005529A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2873881A1 (en) * 2012-05-18 2013-11-21 Stephen Bruce Fleming Combination treatments and compositions for wound healing
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
BR112020018117A2 (pt) 2018-03-07 2020-12-22 Transgene Vírus da pseudovaríola (pcpv), métodos para gerar o pcpv e para amplificar o pcpv, composição, método de tratamento, método para inibir o crescimento de células tumorais, uso ou método e método para induzir ou estimular e/ ou reorientar uma resposta imune
LT3906970T (lt) * 2020-05-08 2022-10-10 Aicuris Gmbh & Co. Kg Parapoxvirus, skirtas adaptacijai prie koronaviruso infekcijos ir gydymui
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU718141B2 (en) * 1996-02-28 2000-04-06 Bayer Healthcare Ag Parapoxviruses which contain foreign DNA, their preparation and their use in vaccines
ES2125846T3 (es) * 1996-04-15 2001-12-16 Anton Prof Dr Med Vet Dr Mayr Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.
DE19922407A1 (de) 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
CA2415397C (en) * 2000-07-11 2011-04-26 Bayer Aktiengesellschaft Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer

Also Published As

Publication number Publication date
US8343478B2 (en) 2013-01-01
US20100255032A1 (en) 2010-10-07
ES2330540T3 (es) 2009-12-11
CA2573204C (en) 2011-09-20
CN1984666A (zh) 2007-06-20
BRPI0513321B1 (pt) 2022-03-08
DK1765370T3 (da) 2009-11-02
PT1765370E (pt) 2009-09-23
ATE442155T1 (de) 2009-09-15
CN103800382A (zh) 2014-05-21
EP1765370A1 (en) 2007-03-28
HK1097467A1 (en) 2007-06-29
JP4897677B2 (ja) 2012-03-14
BRPI0513321A (pt) 2008-05-06
WO2006005529A1 (en) 2006-01-19
DE602005016552D1 (de) 2009-10-22
EP1765370B1 (en) 2009-09-09
CA2573204A1 (en) 2006-01-19
JP2008505952A (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
TW200510343A (en) Substituted dihydroquinazolines
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
SG163517A1 (en) Antiviral compounds and methods
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
WO2005063734A3 (de) Substituierte thiophene
MY141025A (en) Dose forms
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
AU2003291998A8 (en) Method and compositions for identifying anti-hiv therapeutic compounds
IL158558A0 (en) Antiviral compounds
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
MXPA04006572A (es) Terapia de combinacion antivirica.
NO20052310L (no) Posisjonsisomerer av PEG IFN alfa 2A.
IL203873A0 (en) Novel targets and compounds for therapeutic intervention of hiv infection
PT1765370E (pt) Parapoxvirus em associação com outros agentes antivirais para o tratamento de hiv/sida
TW200633718A (en) Treatment of hepatitis c in the asian population
MX2024010673A (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos.
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
WO2006043153A3 (en) Use of zinc and copper chelators for the treatment of viral diseases
WO2004052905A3 (en) Antiviral nucleoside derivatives
TW200700411A (en) Heterocyclylamide-substituted imidazoles
WO2004043402A3 (en) Modified nucleosides as antiviral agents
WO2008030853A3 (en) Combination therapy for human immunodeficiency virus infection
WO2005058237A3 (en) Treatment of aids